Advanced Proteome Therapeutics Corporation V.APC.H

Advanced Proteome receives patent for cancer proteins

[Aj1985]

2017-01-17 13:04 ET - News Release Dr. Allen Krantz reports ADVANCED PROTEOME THERAPEUTICS CORPORATION ANNOUNCES ISSUANCE OF U.S. PATENT COVERING NOVEL MOLECULES FOR THE TREATMENT OF CANCER Advanced Proteome Therapeutics Corp. has been issued U.S. patent application 14/400,190, titled "Site-Specific Labelling and Targeted Delivery of Proteins for the Treatment of Cancer." The patent covers multiple examples of novel molecular entities, linked proteins, designed to increase potency, as well as duration of action, against tumour cells compared with the corresponding single proteins. The patent also covers methods of treating cancer in a patient, comprising administering an effective amount of the pharmaceutical composition of such linked proteins. "The issuance of this patent is an important milestone for APC that strengthens our overall patent position and provides options for combination immunotherapy," said Dr. Allen Krantz, the company's chief executive officer. "As we move forward with our antibody drug conjugate programs, we now have additional incentive to investigate possibilities for such combination therapy." Certain members of this new class of compounds produced by APC have exhibited the ability to decrease tumour growth in animal models independently and, to a greater extent, in combination with checkpoint inhibitors. Compounds of this class have also been demonstrated to block upregulation of the immune checkpoint inhibitor PD-L1 by TAM (tyrosine kinase) receptors in model studies. The expression of TAM receptors in multiple tumour types correlates with tumour grade and emergence of resistance to targeted therapeutics. The significance of these findings is heightened by the fact that anti-PD-L1 agents have demonstrated marked clinical success in a wide range of malignancies by providing durable benefits with minimal toxicities and opened up novel avenues for cancer immunotherapy. About APC Advanced Proteome Therapeutics is advancing a site-specific protein modification technology platform to enable the development of superior protein therapeutics.